866-997-4948(US-Canada Toll Free)

Gout Therapeutic Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2019 - 2027

Published By :

Transparency Market Research

Published Date : May 2019

Category :

Pharmaceutical

No. of Pages : 165 Pages

Global Gout Therapeutics Market: Overview

This report studies the current as well as future prospects of the global gout therapeutic market. Stakeholders of this report include companies and intermediaries engaged in the manufacture, commercialization, and provision of gout therapeutic and new players planning to enter the market.

The report comprises an elaborate executive summary, along with a market snapshot, providing overall information on various segments considered in the scope of the study. The section also provides information and data analysis of the global gout therapeutic market in terms of drug type, distribution channel, and region.

Global Gout Therapeutics Market: Key Segments

The global gout therapeutic market has been segmented based on drug type, distribution channel, and region. In terms of drug type, the global market has been classified into colchicine, antihyperuricemic agents (urate-lowering drugs), non-steroidal anti-inflammatory drugs (NSAIDs), corticosteroids, and biologic response modifiers (Biologics).  

Based on distribution channel, the global gout therapeutic market has been divided into hospital pharmacy, retail pharmacy, and online pharmacy. The retail pharmacy segment is expected to dominate the global gout therapeutic market during the forecast period.

Research Approach

The bottom-up approach has been employed to determine the size of the global gout therapeutic market, using various market indicators obtained from secondary sources, which included analysis of launched products and mapping of demand for gout therapeutic of top market players in specific regions.

The top-down approach has been used to derive the market size of different product segments, wherein market size of parent market was obtained through secondary sources and analyzed for sales by narrowing down to revenue percentage for product segment through extensive analysis of investor presentations, press releases, primary interviews, and others.

Data triangulation is based on both secondary research (top-down and bottom-up approaches) and primary research. Moreover, historical year-on-year growth has been taken into consideration while estimating the market size. Market value and forecast, in terms of US$ Mn, for each segment has been provided for the period from 2017 to 2027.

The report also provides compound annual growth rate (CAGR %) for each segment for the forecast period from 2019 to 2027, considering 2018 as the base year.

The overview section of the report explores market dynamics such as drivers, restraints, opportunities, and key trends that have significant impact on the global gout therapeutic market and could influence it in the near future.

Market attractiveness analysis has been provided to explain the intensity of competition in the market across regions. These analyses are likely to help market players take strategic decisions to strengthen their positions and grow their share in the global gout therapeutic market. The report also comprises pipeline analysis and epidemiological overview of gout.

Global Gout Therapeutics Market: Regional Outlook

In terms of region, the global gout therapeutic market has been segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. Market size and forecast for each of these regions have been provided for the period from 2017 to 2027, along with their respective CAGRs for the forecast period from 2019 to 2027, considering 2018 as the base year.

The report also provides market size and forecast for major countries in the above mentioned regions. A detailed qualitative analysis of factors responsible for driving and restraining the market and growth opportunities has been provided in the overview section.

Companies Mentioned in the Report

Some of the major players operating in the global gout therapeutics market are

  • Takeda Pharmaceutical Company Limited
  • Teijin Pharma Limited.
    Novartis AG, Mylan N.V.
  • Horizon Pharma plc
  • Teva Pharmaceutical Industries Ltd.
  • Hikma Pharmaceuticals PLC
  • Iroko Pharmaceuticals, LLC
  • MERCK & CO., Inc.

The global gout therapeutics market has been segmented as follows:

Global Gout Therapeutics Market, by Drug Type

  • Colchicine
  • Antihyperuricemic Agents (Urate-Lowering Drugs)
  • Non-steroidal Anti-inflammatory Drugs (NSAIDs)
  • Corticosteroids
  • Biologic Response Modifiers (Biologics)

Global Gout Therapeutics Market, by Distribution Channel

  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacy

Global Gout Therapeutics Market, by Region

  • North America
  • U.S.
  • Canada
  • Europe
  • U.K.
  • Germany
  • France
  • Italy
  • Spain
  • Rest of Europe
  • Asia Pacific
  • China
  • India
  • Japan
  • Australia & New Zealand
  • Rest of Asia Pacific
  • Latin America
  • Brazil
  • Mexico
  • Rest of Latin America
  • Middle East & Africa
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

1.Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary : Global Gout Therapeutics Market 

4. Market Overview
4.1. Introduction
4.1.1. Component Definition
4.1.2. Industry Evolution / Developments
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Gout Therapeutics Market Analysis and Forecast, 2017–2027
4.4.1. Market Revenue Projections (US$ Mn)
4.5. Porter’s Five Force Analysis

5. Market Outlook
5.1.Epidemiological Overview of Gout Arthritis
5.2.Pipeline Analysis

6. Global Gout Therapeutics Market Analysis and Forecast, by Component 
6.1. Introduction & Definition
6.2. Key Findings / Developments
6.3. Global Gout Therapeutics Market Value Forecast, by Drug Type, 2017–2027
6.3.1. Colchicine
6.3.2. Antihyperuricemic agents (Urate-Lowering Drugs) 
6.3.3. Non-steroidal Anti-inflammatory Drugs (NSAIDs)
6.3.4. Corticosteroids
6.3.5. Biologic Response Modifiers (Biologics)
6.4. Global Gout Therapeutics Market Attractiveness, by Drug Type

7 Global Gout Therapeutics Market Analysis and Forecast, by Distribution Channel 
7.1. Introduction & Definition
7.2. Key Findings / Developments
7.3. Global Gout Therapeutics Market Value Forecast, by Distribution Channel, 2017–2027
7.3.1. Hospital Pharmacy
7.3.2. Retail Pharmacy
7.3.3. Online Pharmacy
7.4. Global Gout Therapeutics Market Attractiveness, by Distribution Channel 

8. Global Gout Therapeutics Market Analysis and Forecast, by Region
8.1. Key Findings
8.2. Global Gout Therapeutics Market Value Forecast, by Region
8.2.1. North America 
8.2.2. Europe 
8.2.3. Asia Pacific 
8.2.4. Latin America 
8.2.5. Middle East & Africa 
8.3. Global Gout Therapeutics Market Attractiveness, by Country/Region

9. North America Gout Therapeutics Market Analysis and Forecast
9.1. Introduction
9.1.1. Key Findings
9.2. North America Gout Therapeutics Market Value Forecast, by Drug Type, 2017–2027
9.2.1. Colchicine
9.2.2. Antihyperuricemic agents (Urate-Lowering Drugs) 
9.2.3. Non-steroidal Anti-inflammatory Drugs (NSAIDs)
9.2.4. Corticosteroids
9.2.5. Biologic Response Modifiers (Biologics)
9.3. North America Gout Therapeutics Market Value Forecast, by Distribution Channel, 2017–2027
9.3.1. Hospital Pharmacy
9.3.2. Retail Pharmacy
9.3.3. Online Pharmacy
9.4. North America Gout Therapeutics Market Value Forecast, by Country, 2017–2027
9.4.1. U.S.
9.4.2. Canada
9.5. North America Gout Therapeutics Market Attractiveness Analysis 
9.5.1. By Drug Type
9.5.2. By Distribution Channel 
9.5.3. By Country

10. Europe Gout Therapeutics Market Analysis and Forecast
10.1. Introduction
10.1.1. Key Findings
10.2. Europe Gout Therapeutics Market Value Forecast, by Drug Type, 2017–2027
10.2.1. Colchicine
10.2.2. Antihyperuricemic agents (Urate-Lowering Drugs) 
10.2.3. Non-steroidal Anti-inflammatory Drugs (NSAIDs)
10.2.4. Corticosteroids
10.2.5. Biologic Response Modifiers (Biologics)
10.3. Europe Gout Therapeutics Market Value Forecast, by Distribution Channel, 2017–2027
10.3.1. Hospital Pharmacy
10.3.2. Retail Pharmacy
10.3.3. Online Pharmacy
10.4. Europe Gout Therapeutics Market Value Forecast, by Country/Sub-region, 2017–2027
10.4.1. Germany
10.4.2. U.K.
10.4.3. France
10.4.4. Spain
10.4.5. Italy
10.4.6. Rest of Europe
10.5. Europe Gout Therapeutics Market Attractiveness Analysis 
10.5.1. By Drug Type 
10.5.2. By Distribution Channel 
10.5.3. By Country/Sub-region

11. Asia Pacific Gout Therapeutics Market Analysis and Forecast
11.1.Introduction
11.1.1. Key Findings
11.2. Asia Pacific Gout Therapeutics Market Value Forecast, by Drug Type, 2017–2027
11.2.1. Colchicine
11.2.2. Antihyperuricemic agents (Urate-Lowering Drugs) 
11.2.3. Non-steroidal Anti-inflammatory Drugs (NSAIDs)
11.2.4. Corticosteroids
11.2.5. Biologic Response Modifiers (Biologics)
11.3. Asia Pacific Gout Therapeutics Market Value Forecast, by Distribution Channel, 2017–2027
11.3.1. Hospital Pharmacy
11.3.2. Retail Pharmacy
11.3.3. Online Pharmacy
11.4. Asia Pacific Gout Therapeutics Market Value Forecast, by Country/Sub-region, 2017–2027
11.4.1. China
11.4.2. Japan
11.4.3. India
11.4.4. Australia & New Zealand
11.4.5. Rest of Asia Pacific
11.5. Asia Pacific Gout Therapeutics Market Attractiveness Analysis 
11.5.1. By Drug Type 
11.5.2. By Distribution Channel 
11.5.3. By Country/Sub-region

12. Latin America Gout Therapeutics Market Analysis and Forecast
12.1.Introduction
12.1.1. Key Findings
12.2. Latin America Gout Therapeutics Market Value Forecast, by Drug Type, 2017–2027
12.2.1. Colchicine
12.2.2. Antihyperuricemic agents (Urate-Lowering Drugs) 
12.2.3. Non-steroidal Anti-inflammatory Drugs (NSAIDs)
12.2.4. Corticosteroids
12.2.5. Biologic Response Modifiers (Biologics)
12.3. Latin America Gout Therapeutics Market Value Forecast, by Distribution Channel, 2017–2027
12.3.1. Hospital Pharmacy
12.3.2. Retail Pharmacy
12.3.3. Online Pharmacy
12.4. Latin America Gout Therapeutics Market Value Forecast, by Country/Sub-region, 2017–2027
12.4.1. Brazil
12.4.2. Mexico
12.4.3. Rest of Latin America
12.5. Latin America Gout Therapeutics Market Attractiveness Analysis 
12.5.1. By Drug Type
12.5.2. By Distribution Channel 
12.5.3. By Country/Sub-region

13. Middle East & Africa Gout Therapeutics Market Analysis and Forecast
13.1.Introduction
13.1.1. Key Findings
13.2. Middle East & Africa Gout Therapeutics Market Value Forecast, by Drug Type, 2017–2027
13.2.1. Colchicine
13.2.2. Antihyperuricemic agents (Urate-Lowering Drugs) 
13.2.3. Non-steroidal Anti-inflammatory Drugs (NSAIDs)
13.2.4. Corticosteroids
13.2.5. Biologic Response Modifiers (Biologics)
13.3. Middle East & Africa Gout Therapeutics Market Value Forecast, by Distribution Channel, 2017–2027
13.3.1. Hospital Pharmacy
13.3.2. Retail Pharmacy
13.3.3. Online Pharmacy
13.4. Middle East & Africa Gout Therapeutics Market Value Forecast, by Country/Sub-region, 2017–2027
13.4.1. GCC Countries
13.4.2. South Africa
13.4.3. Rest of Middle East & Africa
13.5.Market Attractiveness Analysis 
13.5.1. By Drug Type
13.5.2. By Distribution Channel 
13.5.3. By Country/Sub-region

14. Competition Landscape
14.1. Company Profiles
14.1.1. Takeda Pharmaceutical Company Limited
14.1.1.1. Company Overview (HQ, Business Segments, Employee Strengths)
14.1.1.2 Product Portfolio
14.1.1.3. SWOT Analysis 
14.1.1.4. Strategic Overview
14.1.1.5. Financial Overview
14.1.2. Teijin Pharma Limited
14.1.2.1. Company Overview (HQ, Business Segments, Employee Strengths)
14.1.2.2 Product Portfolio
14.1.2.3. SWOT Analysis 
14.1.2.4. Strategic Overview
14.1.3. Novartis AG
14.1.3.1. Company Overview (HQ, Business Segments, Employee Strengths)
14.1.3.2 Product Portfolio
14.1.3.3. SWOT Analysis 
14.1.3.4. Strategic Overview
14.1.3.5. Financial Overview
14.1.4. Mylan N.V.
14.1.4.1. Company Overview (HQ, Business Segments, Employee Strengths)
14.1.4.2 Product Portfolio
14.1.4.3. SWOT Analysis 
14.1.4.4. Strategic Overview
14.1.4.5. Financial Overview
14.1.5. Horizon Pharma plc.
14.1.5.1. Company Overview (HQ, Business Segments, Employee Strengths)
14.1.5.2 Product Portfolio
14.1.5.3. SWOT Analysis 
14.1.5.4. Strategic Overview
14.1.5.5. Financial Overview
14.1.6. Teva Pharmaceutical Industries Ltd.
14.1.6.1. Company Overview (HQ, Business Segments, Employee Strengths)
14.1.6.2 Product Portfolio
14.1.6.3. SWOT Analysis 
14.1.6.4. Strategic Overview
14.1.6.5. Financial Overview
14.1.7 Hikma Pharmaceuticals PLC
14.1.7.1. Company Overview (HQ, Business Segments, Employee Strengths)
14.1.7.2 Product Portfolio
14.1.7.3. SWOT Analysis 
14.1.7.4. Strategic Overview
14.1.7.5. Financial Overview
14.1.8. Iroko Pharmaceuticals, LLC 
14.1.7.1. Company Overview (HQ, Business Segments, Employee Strengths)
14.1.7.2 Product Portfolio
14.1.7.3. SWOT Analysis 
14.1.7.4. Strategic Overview
14.1.9. MERCK & CO., Inc.
14.1.9.1. Company Overview (HQ, Business Segments, Employee Strengths)
14.1.9.2 Product Portfolio
14.1.9.3. SWOT Analysis 
14.1.9.4. Strategic Overview
14.1.9.5. Financial Overview

List of Table

List of Tables

Table 01: Global Gout Therapeutics Market Value (US$ Mn) Forecast, by Drug Type, 2017–2027
Table 2: Global Gout Therapeutics Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2027
Table 3: Global Gout Therapeutics Market Value (US$ Mn) Forecast, by Region, 2017–2027
Table 4: North America Gout Therapeutics Market Value (US$ Mn) Forecast, by Country, 2017–2027
Table 5: North America Gout Therapeutics Market Value (US$ Mn) Forecast, by Drug Type, 2017–2027
Table 6: North America Gout Therapeutics Market Value (US$ Mn) Forecast, by Distribution Channel, 
2017–2027
Table 7: Europe Gout Therapeutics Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2027
Table 8: Europe Gout Therapeutics Market Value (US$ Mn) Forecast, by Drug Type, 2017–2027
Table 9: Europe Gout Therapeutics Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2027
Table 10: Asia Pacific Gout Therapeutics Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2027
Table 11: Asia Pacific Gout Therapeutics Market Value (US$ Mn) Forecast, by Drug Type, 2017–2027
Table 12: Asia Pacific Gout Therapeutics Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2027
Table 13: Latin America Gout Therapeutics Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2027
Table 14: Latin America Gout Therapeutics Market Value (US$ Mn) Forecast, by Drug Type, 2017–2027
Table 15: Latin America Gout Therapeutics Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2027
Table 16: Middle East & Africa Gout Therapeutics Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2027
Table 17: Middle East & Africa Gout Therapeutics Market Value (US$ Mn) Forecast, by Drug Type, 2017–2027
Table 18: Middle East & Africa Gout Therapeutics Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2027

List of Chart

List of Figures

Figure 1: Global Gout Therapeutics Market Value (US$ Mn), by Drug Type 2018 (A).
Figure 2: Global Gout Therapeutics Market Share (%), by Distribution Channel, 2017 (A).
Figure 3: Opportunity Map, Drug type.
Figure 4: Opportunity Map, Distribution Channel.
Figure 5: Key Industry Developments.
Figure 6: Global Gout Therapeutics Market Value (US$ Mn) Forecast, 2017–2027
Figure 7: Global Gout Therapeutics Market Value Share, by Drug Type (2018)
Figure 8: Global Gout Therapeutics Market Value Share, by Distribution channel (2018)
Figure 9: Global Gout Therapeutics Market Value Share, by Region (2018)
Figure 10: Global Gout Therapeutics Market Value Split, by Type (2018)
Figure 11: Global Gout Therapeutics Market Value Split, by Region (2018).
Figure 12: Global Gout Therapeutics Market Value Split, by Distribution Channel (2018)
Figure 13: Global Gout Therapeutics Market Value Share Analysis, by Drug Type, 2018 and 2027
Figure 14: Global Gout Therapeutics Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), by Antihyperuricemic Agents (Urate-Lowering Drugs), 2017–2027
Figure 15: Global Gout Therapeutics Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), by Non-steroidal Anti-inflammatory Drugs (NSAIDs), 2017–2027
Figure 16: Global Gout Therapeutics Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), by Corticosteroids, 2017–2027
Figure 17: Global Gout Therapeutics Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), by Biologics, 2017–2027
Figure 18: Global Gout Therapeutics Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), by Colchicine, 2017–2027
Figure 19: Global Gout Therapeutics Market Attractiveness Analysis, by Drug Type, 2019–2027
Figure 20: Global Gout Therapeutics Market Value Share Analysis, by Distribution Channel, 2018 and 2027
Figure 21: Global Gout Therapeutics Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), by Retail Pharmacy, 2017–2027
Figure 22: Global Gout Therapeutics Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), by Hospital Pharmacy, 2017–2027
Figure 23: Global Gout Therapeutics Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), by Online Pharmacy, 2017-2027
Figure 24: Global Gout Therapeutics Market Attractiveness Analysis, by Distribution Channel, 2019–2027
Figure 25: Global Gout Therapeutics Market Value Share Analysis, by Region, 2018 and 2027
Figure 26: Global Gout Therapeutics Market Attractiveness Analysis, by Region, 2019?2027
Figure 27: North America Gout Therapeutics Market Value Share Analysis, by Country/Sub-region, 2018 and 2027
Figure 28: North America Gout Therapeutics Market Value Share Analysis, by Drug Type, 2018 and 2027
Figure 29: North America Gout Therapeutics Market Value Share Analysis, by Distribution Channel, 2018 and 2027
Figure 30: North America Gout Therapeutics Market Attractiveness Analysis, by Drug Type, 2019–2027
Figure 31: North America Gout Therapeutics Market Attractiveness Analysis, by Distribution Channel, 2019–2027
Figure 32: North America Gout Therapeutics Market Attractiveness Analysis, by Country, 2019–2027
Figure 33: Europe Gout Therapeutics Market Value Share Analysis, by Country/Sub-region, 2018 and 2027
Figure 34: Europe Gout Therapeutics Market Value Share Analysis, by Drug Type, 2018 and 2027
Figure 35: Europe Gout Therapeutics Market Value Share Analysis, by Distribution Channel, 2018 and 2027
Figure 36: Europe Gout Therapeutics Market Attractiveness Analysis, by Drug Type, 2019–2027
Figure 37: Europe Gout Therapeutics Market Attractiveness Analysis, by Distribution Channel, 2019–2027
Figure 38: Europe Gout Therapeutics Market Attractiveness Analysis, by Country/Sub-region, 2019–2027
Figure 39: Asia Pacific Gout Therapeutics Market Value Share Analysis, by Country/Sub-region, 2018 and 2027
Figure 40: Asia Pacific Gout Therapeutics Market Value Share Analysis, by Drug Type, 2018 and 2027
Figure 41: Asia Pacific Gout Therapeutics Market Value Share Analysis, by Distribution Channel, 2018 and 2027
Figure 42: Asia Pacific Gout Therapeutics Market Attractiveness Analysis, by Drug Type, 2019–2027
Figure 43: Asia Pacific Gout Therapeutics Market Attractiveness Analysis, by Distribution Channel, 2019–2027
Figure 44: Asia Pacific Gout Therapeutics Market Attractiveness Analysis, by Country/Sub-region, 2019–2027
Figure 45: Latin America Gout Therapeutics Market Value Share Analysis, by Country/Sub-region, 2018 and 2027
Figure 46: Latin America Gout Therapeutics Market Value Share Analysis, by Drug Type, 2018 and 2027
Figure 47: Latin America Gout Therapeutics Market Value Share Analysis, by Distribution Channel, 2018 and 2027
Figure 48: Latin America Gout Therapeutics Market Attractiveness Analysis, by Drug Type, 2019–2027
Figure 49: Latin America Gout Therapeutics Market Attractiveness Analysis, by Distribution Channel, 2019–2027
Figure 50: Latin America Gout Therapeutics Market Attractiveness Analysis, by Country/Sub-region, 2019–2027
Figure 51: Middle East & Africa Gout Therapeutics Market Value Share Analysis, by Country/Sub-region, 2018 and 2027
Figure 52: Middle East & Africa Gout Therapeutics Market Value Share Analysis, by Drug Type, 2018 and 2027
Figure 53: Middle East & Africa Gout Therapeutics Market Value Share Analysis, by Distribution Channel, 2018 and 2027
Figure 54: Middle East & Africa Gout Therapeutics Market Attractiveness Analysis, by Drug Type, 2019–2027
Figure 55: Middle East & Africa Gout Therapeutics Market Attractiveness Analysis, by Distribution Channel, 2019–2027
Figure 56: Middle East & Africa Gout Therapeutics Market Attractiveness Analysis, by Country/Sub-region, 2019–2027
Figure 57: Takeda Breakdown of Net Sales, by Region.
Figure 58: Takeda Revenue (US$ Bn) & Y-o-Y Growth (%), 2014–2018
Figure 59: Takeda R&D Expenses (US$ Bn), 2016–2018
Figure 60: Novartis AG Breakdown of Net Sales, by Region, 2018
Figure 61: Novartis AG Breakdown of Net Sales, by Business Segment, 2018.
Figure 62: Novartis AG Revenue (US$ Bn) and Y-o-Y Growth (%), 2015–2018.
Figure 63: Novartis AG R&D Expenses (US$ Mn), 2016–2018.
Figure 64: Teva Pharmaceutical Revenue (US$ Bn) & Y-o-Y Growth (%), 2013–2018.
Figure 65: Teva Pharmaceutical R&D Expenses (US$ Bn), 2016–2018.
Figure 66: Teva Pharmaceutical Breakdown of Net Sales, By Region 2018.
Figure 67: Teva Pharmaceutical Breakdown of Net Sales, (Overall Company Level), 2018.
Figure 68: Mylan N.V. Revenue (US$ Mn) and Y-o-Y Growth (%), 2014-2018
Figure 69: Mylan N.V. R&D Expenses (US$ Mn), 2016–2018
Figure 70: Mylan N.V.  Breakdown of Net Sales (%), by Region, 2018.
Figure 71: Breakdown of Net Sales (%), by Business Segment, 2018.
Figure 72: Horizon Pharma plc Revenue (US$ Mn) and Y-o-Y Growth (%), 2014-2018.
Figure 73: Horizon Pharma plc R&D Expenses (US$ Mn), 2016–2018.
Figure 74: Horizon Pharma plc Breakdown of Net Sales, by Business Segment, 2018.
Figure 75: Horizon Pharma plc Breakdown of Net Sales, by Region, 2018.
Figure 76: Hikma Pharmaceuticals PLC Revenue (US$ Mn) and Y-o-Y Growth (%), 2014-2018
Figure 77: Hikma Pharmaceuticals PLC R&D Expenses (US$ Mn), 2016–2018.
Figure 78: Hikma Pharmaceuticals PLC Breakdown of Net Sales, by Business Segment, 2018
Figure 79: Hikma Pharmaceuticals PLC Breakdown of Net Sales, by Region, 2018.
Figure 80: MERCK & CO., Inc Revenue (US$ Mn) and Y-o-Y Growth (%), 2014-2018
Figure 81: MERCK & CO., Inc PLC R&D Expenses (US$ Mn), 2016–2018.
Figure 82 MERCK & CO., Inc PLC Breakdown of Net Sales, by Business Segment, 2018
Figure 83: MERCK & CO., Inc PLC Breakdown of Net Sales, by Region, 2018

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title
  • Company
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *